|
Search concepts
|
|
Selected filters
|
- 6,400 - 6,450 out of 6,984 results
- Export search results
Search results
-
-
-
Applicable categorical structures
Street, R., Johnson, M., Lack, S., Verity, D. & Lan, R.
1/01/10 → 30/06/14
Project: Research
-
A Political Sacred Cow? Housing, tax expenditures and the Australian welfare state
Stebbing, A. & Spies-Butcher, B.
10/01/13 → 10/05/14
Project: Research
-
-
-
A plate washer for preparing live cells for imaging
Connor, M., McMorran, B., Stoodley, M. & Tu, J.
1/01/13 → 31/12/13
Project: Research
-
A pilot study on interpreting in mental health interactions
Hlavac, J. & Orlando, M.
1/08/15 → 1/04/17
Project: Research
-
A pilot study of the personal and professional support needs and future careers of rural and metropolitan hospital pharmacy graduates in NSW, [Funded by NSW Institute of Rural Clinical Services and Training (as part of the Building Rural Research Capacity Programme); Total Awarded: $36,400]
Schofield, D. & Hewetson, M.
1/01/07 → 31/12/08
Project: Research
-
A pilot study of newly-identified low surface brightness galaxies in Virgo
Moore, L.
21/03/06 → 28/03/06
Project: Research
-
A pilot study of comorbidity-adapted exercise for older adults with low back pain.
De Luca, K., French, S., Ferreira, M. L., Hartvigsen, J. & Bierma-Zeinstra, S. M. A.
1/01/20 → 5/02/21
Project: Other
-
A Phase II Trial of single agent CABOZANTINIB in patients with locally advanced or metastatic non-clear cell renal cell carcinoma post immunotherapy or who are unsuitable for immunotherapy (ANZUP 1802)
Gurney, H., Chapman, N., Cunningham, J. & Butala, R.
14/03/19 → 13/03/24
Project: Other
-
CHARIOT: A phase II study evaluating efficacy and safety of Ipilimumab and Nivolumab with neoadjuvant weekly paclitaxel after anthracycline based chemotherapy in high-risk primary triple negative breast cancer, followed by definitive surgery and one year total duration of Nivolumab
Kefford, R. & Cunningham, J.
6/03/19 → 23/01/24
Project: Other
-
A phase II randomised controlled trial of high dose Vitamin D in localised prostate cancer cases with intermediate risk of progression (Pros-D).
Gurney, H., Butala, R., Nair-Shalliker, V., Smith, D., Gebski, V., Patel, M., Frydenberg, M., Gardiner, R., Kimlin, M., Fenech, M. & Gillatt, D.
1/03/16 → …
Project: Research
-
A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer
Gurney, H., Cunningham, J. & Butala, R.
10/10/18 → 6/10/23
Project: Other
-
MISC_AstraZeneca Pty Ltd: A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer
Gurney, H., Butala, R. & Cunningham, J.
5/10/18 → 6/09/23
Project: Other
-
IMbrave050: A phase III, multicentre, randomized, open-label study of atezolizumab (anti-PD-L1 antibody) plus bevacizumab plus bevacizumab versus active surveillance as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after surgical resection or ablationR SURGICAL RESECTION OR ABLATION
Poursoltan, P., Chapman, N. & Parshionikar, A.
11/12/19 → 30/09/24
Project: Other
-
A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]: NATALEE)
Sabanathan, D., Kefford, R. & Cunningham, J.
21/03/19 → 20/03/24
Project: Other
-
WO41994: A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS CABOZANTINIB ALONE IN PATIENTS WITH INOPERABLE, LOCALLY ADVANCED, OR METASTATIC RENAL CELL CARCINOMA WHO EXPERIENCED RADIOGRAPHIC TUMOR PROGRESSION DURING OR AFTER IMMUNE CHECKPOINT INHIBITOR TREATMENT
Gurney, H., Zhang, A. & Chapman, N.
1/08/20 → 25/06/25
Project: Research
-
A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti-PD-L1 Antibody) in combination with adjuvant Anthracycline/Taxane-based Chemotherapy versus Chemotherapy Alone in patients with operable Triple-Negative Breast Cancer
Sabanathan, D., Kefford, R., Chapman, N. & Butala, R.
5/08/19 → 24/10/23
Project: Other
-
IPATunity170: A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Of Ipatasertib In Combination With Atezolizumab And Paclitaxel As A Treatment For Patients With Locally Advanced Unresectable Or Metastatic Triple-Negative Breast Cancer
Kefford, R., Chapman, N., Parshionikar, A. & Rajasekharan Nair, A.
22/11/19 → 30/09/24
Project: Other
-
IPATunity170: A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Of Ipatasertib In Combination With Atezolizumab And Paclitaxel As A Treatment For Patients With Locally Advanced Unresectable Or Metastatic Triple-Negative Breast Cancer
Kefford, R., Chapman, N., Parshionikar, A. & Rajasekharan Nair, A.
22/11/19 → 30/09/24
Project: Other
-
IPATunity170: A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Of Ipatasertib In Combination With Atezolizumab And Paclitaxel As A Treatment For Patients With Locally Advanced Unresectable Or Metastatic Triple-Negative Breast Cancer
Kefford, R., Chapman, N., Parshionikar, A. & Rajasekharan Nair, A.
22/11/19 → 30/09/24
Project: Other
-
IPATunity170: A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Of Ipatasertib In Combination With Atezolizumab And Paclitaxel As A Treatment For Patients With Locally Advanced Unresectable Or Metastatic Triple-Negative Breast Cancer
Kefford, R., Chapman, N., Parshionikar, A. & Rajasekharan Nair, A.
22/11/19 → 30/09/24
Project: Other
-
CS1001/Regorafenib-101: A phase Ib/II multicenter open-label study of CS1001 in combination with regorafenib in patients with advanced or refractory solid tumors
Park, J., Gurney, H., Parshionikar, A., Chapman, N. & Rai, M.
Project: Research
-
CN1-101: A phase I, open label, multi-center,dose escalation clinical study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CN1 in patients with advanced solid tumors or B-cell lymphoma
Park, J., Chapman, N., Gurney, H. & Sabanathan, D.
3/08/20 → 30/06/25
Project: Research
-
Bayer 20510: A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of novel anti-hormonal therapy (NAH) in patients with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH
Gurney, H. & Chapman, N.
1/12/20 → 10/09/25
Project: Research
-
KEYNOTE-905: A Phase 3 Randomized Study of Cystectomy plus Perioperative Pembrolizumab versus Cystectomy Alone in Cisplatin-ineligible Participants with Muscle-invasive Bladder Cancer (MK3475-905)
Zhang, A., Chapman, N. & Parshionikar, A.
13/09/19 → 6/06/24
Project: Other
-
A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined with Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients with Previously Untreated Advanced Renal Cell Carcinoma
Gurney, H., Chapman, N. & Butala, R.
28/02/19 → 27/02/24
Project: Other
-
AMPLITUDE: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Gurney, H. & Chapman, N.
30/11/20 → 15/10/25
Project: Research
-
Checkmate 914: A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse
Gurney, H., Chapman, N. & Zhang, A.
17/08/20 → 4/06/25
Project: Research
-
ADVANCE-outcomes 303: A phase 3 open-label extension (OLE) study to evaluate the long-term safety and efficacy of ralinepag in subjects with World Health Organisation (WHO) Group 1 pulmonary arterial hypertension (PAH): ADP811-303
Brown, M., Butala, R. & Chapman, N.
17/10/19 → 30/06/22
Project: Research
-
M14-533: A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis
Leong, R., Chapman, N., Parshionikar, A. & Rajasekharan Nair, A.
17/12/19 → 26/09/24
Project: Research
-
KEYLYNK-010: A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration resistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy
Gurney, H., Butala, R. & Chapman, N.
9/09/19 → 30/05/24
Project: Other
-
A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer.
Zhang, A., Chapman, N. & Butala, R.
6/08/19 → 18/06/24
Project: Other
-
LEAP-011: A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression: Protocol MK7902-011-00
Zhang, A., Butala, R. & Chapman, N.
13/09/19 → 6/06/24
Project: Research
-
ADVANCE-outcomes: A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH: APD811-301
Brown, M., Butala, R. & Chapman, N.
17/10/19 → 30/06/22
Project: Research
-
ADVANCE capacity: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by Cardiopulmonary Exercise Testing in Subjects with World Health Organization Group 1 Pulmonary Hypertension Who Recently Initiated Therapy
Brown, M., Chapman, N., Rai, M. & Parshionikar, A.
1/07/20 → 31/03/25
Project: Research
-
A Phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2-antibody drug conjugate, versus treatment of investigator’s choice for HER2-positive, unresectable and/or metastatic breast cancer subjects pretreated with prior standard of care HER2 therapies, including T-DM1
Kefford, R., Butala, R. & Cunningham, J.
12/03/19 → 25/11/23
Project: Other
-
A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
Gurney, H., Cunningham, J. & Butala, R.
17/10/18 → 4/09/23
Project: Other
-
VEGA: A Phase 2a Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter, Proof-of-concept Clinical Study to Evaluate the Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
Leong, R., Butala, R. & Chapman, N.
24/09/19 → 11/07/24
Project: Other
-
GALAXI: A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease
Leong, R., Butala, R., Chapman, N., Parshionikar, A. & Rajasekharan Nair, A.
30/09/19 → 7/05/24
Project: Research
-
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer
Gurney, H., Cunningham, J. & Butala, R.
1/12/18 → 30/11/23
Project: Other
-
MISC_Covance Chiltern: A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting Programmed Death Ligand 1 (PD-L1) Protein in Patients with Advanced Solid Tumors
Gurney, H., Butala, R. & Cunningham, J.
16/07/18 → 15/07/23
Project: Other
-
Harbour Biomed 4003.1: A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of HBM4003 in Subjects with Advanced Solid Tumors
Gurney, H., Chapman, N., Butala, R., Parshionikar, A. & Rajasekharan Nair, A.
30/09/19 → 30/09/24
Project: Other
-
ZN-c5-002: A Phase 1 Open-Label, Multicenter Study to Evaluate Biomarkers for ZN-c5 in Subjects with EstrogenReceptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
Sabanathan, D., Park, J. & Chapman, N.
15/10/20 → 14/10/25
Project: Research